MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Michal Šmída(Central European Institute of Technology), Sebastian Nijman(Austrian Academy of Sciences)
Cited by 45
Related Papers
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
|Clinical Cancer Research|2021|44
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
|PLoS ONE|2020|25